SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India - Quaterly Results

22 Jul 2026 Evaluate
A slight decline in the revenue of Rs. 8018.77 millions was seen for the June 2026 quarter as against Rs. 8102.08 millions during year-ago period.Net profit showed a marginal rise at Rs. 717.46 millions for the quarter ended June 2026, as compared to corresponding quarter of last year.A decline of 1452.39 millions was observed in the OP in the quarter ended June 2026 from 1567.87 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 8018.77 8102.08 -1.03 8018.77 8102.08 -1.03 34739.60 30301.63 14.65
Other Income 137.84 131.52 4.81 137.84 131.52 4.81 498.03 406.80 22.43
PBIDT 1452.39 1567.87 -7.37 1452.39 1567.87 -7.37 7738.85 6054.84 27.81
Interest 96.14 136.73 -29.69 96.14 136.73 -29.69 614.38 627.80 -2.14
PBDT 1356.25 1309.54 3.57 1356.25 1309.54 3.57 7002.87 5734.54 22.12
Depreciation 390.61 395.07 -1.13 390.61 395.07 -1.13 1644.73 1462.30 12.48
PBT 965.64 914.47 5.60 965.64 914.47 5.60 5358.14 4272.24 25.42
TAX 248.18 219.62 13.00 248.18 219.62 13.00 1351.47 1078.88 25.27
Deferred Tax -17.42 -10.30 69.13 -17.42 -10.30 69.13 -0.08 -19.91 -99.60
PAT 717.46 694.85 3.25 717.46 694.85 3.25 4006.67 3193.36 25.47
Equity 247.80 242.64 2.13 247.80 242.64 2.13 247.80 242.54 2.17
PBIDTM(%) 18.11 19.35 -6.40 18.11 19.35 -6.40 22.28 19.98 11.48

Granules India Share Price

854.45 -21.00 (-2.40%)
22-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1942.95
Dr. Reddys Labs. 1183.00
Cipla 1415.10
Lupin 2405.80
Zydus Lifesciences 1129.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: